Body mass index and efficacy and safety of ticagrelor versus prasugrel in patients with acute coronary syndromes.
暂无分享,去创建一个
H. Schunkert | M. Joner | A. Kastrati | F. Neumann | G. Ndrepepa | Hendrik B. Sager | D. Angiolillo | B. Witzenbichler | D. Sibbing | I. Akin | K. Mayer | S. Kufner | I. Bernlochner | K. Laugwitz | Stefanie Schüpke | G. Richardt | W. Hochholzer | S. Cassese | M. Menichelli | E. Xhepa | J. J. Coughlan | M. Behnes | M. Fusaro | A. Aytekin | S. Lahu | S. Gewalt | H. Sager
[1] S. Pocock,et al. Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. , 2021, Journal of the American College of Cardiology.
[2] X. Rosselló,et al. Survival analyses in cardiovascular research, part II: statistical methods in challenging situations. , 2021, Revista espanola de cardiologia.
[3] X. Rosselló,et al. Survival analyses in cardiovascular research, part I: the essentials. , 2021, Revista espanola de cardiologia.
[4] H. Schunkert,et al. Ticagrelor or Prasugrel in Patients With Acute Coronary Syndromes and Diabetes Mellitus. , 2020, JACC. Cardiovascular interventions.
[5] H. Schunkert,et al. Age- and Weight-Adapted Dose of Prasugrel Versus Standard Dose of Ticagrelor in Patients With Acute Coronary Syndromes , 2020, Annals of Internal Medicine.
[6] M. Price,et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. , 2020, JACC. Cardiovascular interventions.
[7] P. Serruys,et al. The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial , 2020, Clinical Research in Cardiology.
[8] W. Rottbauer,et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. , 2019, The New England journal of medicine.
[9] Jason P. Fine,et al. Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .
[10] H. Suryapranata,et al. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor , 2015, Journal of cardiovascular pharmacology.
[11] M. Hadamitzky,et al. Predictors of antiplatelet response to prasugrel during maintenance treatment , 2015, Platelets.
[12] P. Morange,et al. Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. , 2014, International journal of cardiology.
[13] I. Xanthopoulou,et al. Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. , 2014, American heart journal.
[14] S. James,et al. The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: a retrospective analysis of the FEATHER study. , 2014, Thrombosis research.
[15] A. Loundou,et al. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. , 2014, The American journal of cardiology.
[16] H. Schunkert,et al. Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 Trial , 2014, Journal of Cardiovascular Translational Research.
[17] S. James,et al. Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients , 2013, Journal of Thrombosis and Thrombolysis.
[18] Jeroen J. Bax,et al. Third universal definition of myocardial infarction. , 2012, Global heart.
[19] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[20] R. Califf,et al. Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. , 2010, International journal of cardiology.
[21] A. Kastrati,et al. Impact of body mass index on clinical outcome in patients with acute coronary syndromes treated with percutaneous coronary intervention , 2010, Heart and Vessels.
[22] P. Barragan,et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. , 2009, The American journal of cardiology.
[23] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[24] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[25] A. Kastrati,et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. , 2007, The American journal of cardiology.
[26] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[27] G. Stone,et al. Impact of body mass index on outcomes after percutaneous coronary intervention in patients with acute myocardial infarction. , 2007, The American journal of cardiology.
[28] E. Topol,et al. The relationship of obesity to ischemic outcomes following coronary stent placement in contemporary practice , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[29] J. J. Griffin,et al. Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction. , 2006, American heart journal.
[30] M. Parikh,et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). , 2004, The American journal of cardiology.
[31] C. Macaya,et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? , 2004, The Journal of invasive cardiology.